Prediabetes
Methodology & AI Transparency ⓘ
Prediabetes Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is prediabetes? Prediabetes means that your blood glucose, or blood sugar , levels are higher than normal but not high enough to be called diabetes .
- 2 Real-world patient consensus: Mapped to Type 1 & Type 2 Diabetes under ICD-10-CM E10.8 for Prediabetes clinical workups.
- 3 Typical cash cost range: Primary evaluation for Prediabetes incorporates continuous glucose monitoring in Prediabetes (E10.8: (CGM) glycemic variability) and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Prediabetes monitoring tracks Fasting Insulin [Prediabetes E10.8] toward 3.0 – 7.0 uIU/mL (E10.8).
Ask our AI Specialists anything about Prediabetes
What Is Prediabetes?
What is prediabetes? Prediabetes means that your blood glucose, or blood sugar , levels are higher than normal but not high enough to be called diabetes . Glucose comes from the foods you eat. Too much glucose in your blood can damage your body over time. If you have prediabetes, you are more likely to develop type 2 diabetes , heart disease , and stroke . But if you make some lifestyle changes now, you may be able to delay or prevent type 2 diabetes. What causes prediabetes? Prediabetes usually happens when your body has a problem with insulin. Insulin is a hormone that helps the glucose get into your cells to give them energy.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Prediabetes (E10.8) center on progressive pancreatic beta-cell in Prediabetes (E10.8: exhaustion). Cross-referenced with NIH MeSH (Prediabetic State), targeted diabetes & glucose interventions aim to normalize Fasting Insulin [Prediabetes E10.8].
Common Symptoms & Clinical Signs
- • Your body can't make enough insulin to keep your blood sugar levels at a healthy level
- • Are overweight or have obesity
- • Presentation of Prediabetes (E10.8): elevated fasting blood in Prediabetes (E10.8: glucose or post-meal)
- • Secondary Prediabetes clinical sign: increased thirst [Prediabetes E10.8]
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Prediabetes Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E10.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Insulin [Prediabetes E10.8] | 3.0 – 7.0 uIU/mL (E10.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Prediabetes (E10.8: mg/dL)) | > 85% (E10.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hemoglobin A1c (HbA1c) [Prediabetes E10.8] | 4.8% – 5.6% (< 6.5% clinical target) (E10.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Prediabetes
Treatment selection for Prediabetes depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Prediabetes)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of anti-prediabetic drugs in patients with prediabetes: a: What a 16,610-Participant Study Found Among all the included interventions, GLP-1RAs, GIP/GLP-1RAs, and TZDs demonstrated favorable anti-prediabetic efficacy and acceptable safety. BMC medicine • 2026-02-19 • Meta-Analysis | N = 16,610 | 99/100 | PMID 41715123 ↗ |
| New Insights on Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin: What a 2,539-Participant Study Found In adults with obesity/overweight without type 2 diabetes, tirzepatide treatment was associated with improved β-cell function and insulin sensitivity, partly independent of weight reduction. Diabetes care • 2025-09-01 • Phase III Randomized Trial | N = 2,539 | 96/100 | PMID 40694530 ↗ |
| New Insights on 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and: What a 2,254-Participant Study Found In this trial, we provide results for 3 years of treatment, with the limitation that withdrawn individuals were not followed up after discontinuation. Lancet (London, England) • 2017-04-08 • Randomized Controlled Trial | N = 2,254 | 96/100 | PMID 28237263 ↗ |
| New Insights on Quality of life outcomes with a new sustained‑release pregabalin in a phase 3: What a 296-Participant Study Found Once-daily SR pregabalin (YHD1119) achieved QoL outcomes comparable to twice-daily IR pregabalin across general health status, sleep interference, and global impressions over 12 weeks. Current medical research and opinion • 2026-07-15 • Phase III Randomized Trial | N = 296 | 93/100 | PMID 42622433 ↗ |
| New Insights on Effect of Moderate and Severe Persistent high blood sugar on Outcomes in Patients: What a 1,000-Participant Study Found Persistent high blood sugar, either moderate or severe, increased the risk of death or disability in nondiabetic patients with intracerebral hemorrhage. Stroke • 2022-04-15 • Phase III Randomized Trial | N = 1,000 | 90/100 | PMID 34844422 ↗ |
Prediabetes Patient Community & “People Like Me” Threads
Filter Prediabetes community threads and patient logs by age, biological sex, dosage, and treatment duration.